Maxmed Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 2.50 Cr
as on 16-11-2024
- Company Age 20 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 66.42 Cr
as on 16-11-2024
- Satisfied Charges ₹ 1.50 Cr
as on 16-11-2024
- Revenue -9.59%
(FY 2023)
- Profit -28.14%
(FY 2023)
- Ebitda -19.22%
(FY 2023)
- Net Worth 5.81%
(FY 2023)
- Total Assets 12.35%
(FY 2023)
About Maxmed Life Sciences
The Corporate was formerly known as Kk Maxmed Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 2.50 Cr.
The company currently has active open charges totaling ₹66.42 Cr. The company has closed loans amounting to ₹1.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjeev Wasan, Shubham Wasan, and Vandana Wasan serve as directors at the Company.
- CIN/LLPIN
U24232DL2004PTC126912
- Company No.
126912
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Maxmed Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shubham Wasan  | Director | 01-Jul-2019 | Current |
| Sanjeev Wasan | Director | 14-Jun-2004 | Current |
| Vandana Wasan | Additional Director | 09-Nov-2024 | Current |
Financial Performance of Maxmed Life Sciences.
Maxmed Life Sciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.59% decrease. The company also saw a substantial fall in profitability, with a 28.14% decrease in profit. The company's net worth moved up by a moderate rise of 5.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxmed Life Sciences?
In 2023, Maxmed Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Jan 2024 | ₹21.00 Cr | Open |
Hdfc Bank Limited Creation Date: 25 May 2023 | ₹3.00 M | Open |
Others Creation Date: 03 Oct 2020 | ₹1.20 M | Open |
How Many Employees Work at Maxmed Life Sciences?
Maxmed Life Sciences has a workforce of 42 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxmed Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxmed Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
